U.S. FDA declines to approve United-MannKind's lung disease therapy
Reuters
Published Oct 18, 2021 07:09AM ET
Updated Oct 18, 2021 09:23AM ET
By Manas Mishra and Bhanvi Satija
(Reuters) -The U.S. Food and Drug Administration declined to approve United Therapeutics (NASDAQ:UTHR) and MannKind (NASDAQ:MNKD) Corp's lung disease therapy, citing an inspection issue at a third-party facility, the companies said on Monday.
The therapy is a drug-device combination that uses United Therapeutics' approved treatment, Tyvaso, in combination with MannKind's portable inhaler.
MannKind's Dreamboat device is a small and portable dry powder inhaler, making its administration more convenient than the traditional nebulized therapy.
MannKind's shares fell 29.3% to $3.60 in premarket trading, while United Therapeutics' shares were down 2.5% at $182.42.
The companies said the agency did not cite any operational shortcomings at MannKind's device manufacturing and testing facility. The inspection was related to a facility that performs analytical testing of a drug substance used in the therapy.
MannKind told Reuters that it remains confident the inspection issue would be resolved "in short order".
The companies were seeking approval of Tyvaso DPI to treat patients with pulmonary arterial hypertension (PAH), as well as PAH associated with interstitial lung disease.
A favorable label for the therapy appears likely, and its approval is a matter of "when" and not "if", J.P. Morgan analyst Jessica Fye said in a note.
While PAH is a type of high blood pressure that affects blood vessels in the lungs, PH-ILDs are a group of diseases that cause inflammation and scarring of the lung tissue, making it harder to breathe.
MannKind and United Therapeutics began collaborating on the pulmonary hypertension product in September 2018. MannKind manufactures the clinical and commercial supplies, while United is responsible for development and regulatory activities.
United said it now expects to launch the product no later than the summer of 2022.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.